Feng Yu is a Distinguished Associate Professor at the Institute of Cell and Gene Technology, Shenzhen University of Advanced Technology (SUAT). He previously served as Deputy Director of the Guangdong-Hong Kong-Macao Branch of BGI-Research and as a Visiting Professor at Shanxi Medical University. He has been recognized with prestigious talent titles, including Shenzhen High-Level Overseas Talent (Category C) and Yantian District Wutong Phoenix Talent (Category C).

Dr. Feng Yu’s research focuses on the development of spatial multi-omics technologies, with a particular emphasis on tumor immunology and autoimmune diseases. He is dedicated to uncovering the fundamental mechanisms of immune dysregulation and creating precision diagnostic and therapeutic strategies for major chronic conditions. In recent years, he has published multiple high-impact papers as first or corresponding author in leading journals such asCell,Science Translational Medicine, andNature Communications. His work has been supported by the Shenzhen Medical Research Special Fund (Youth Project) and several national-level grants.

·2025.05 – 2026.03 Deputy Director, Guangdong-Hong Kong-Macao Branch, BGI-Research

·2023.01 – 2025.04 Special Scientist, BGI-Research

·2020.11–2022.12 Postdoctoral Researcher, BGI-Research

·2016.08 – 2020.10 Ph.D., School of Biomedical Sciences, The Chinese University of Hong Kong

·2012.09 – 2016.06  B.Sc. in Life Sciences and Technology(National Base Class),Wuhan University

Spatial omics technology development, tumor immunology, autoimmune diseases, immune receptors, antibody drug development, protein structure, artificial intelligence

Research Projects

·Shenzhen Medical Research Special Fund – Original Project(January2026–December2028),RMB 800,000, Principal Investigator

·National Health Commission Science and Technology Innovation 2030 Major Project – “Research on Prevention and Treatment of Cancer, Cardiovascular and Cerebrovascular, Respiratory, and Metabolic Diseases” (January 2025 – December 2028), RMB 8,000,000, Participant

·National Natural Science Foundation of China – Special Project (January 1, 2026 – December 31, 2028), RMB 2,700,000, Ongoing, Participant

Recent Publications (Last Five Years)

1.Xiaojuan Zhan*, Mengye Huang*, Yang Zhang*, Zhong Liu*, Chengwu Liu, Yanying Guo, Yi Liu,Wenwen Zhou, Yixin Yan, Hui Zeng, Yingqi Dong, Xuan Dong, Xiaoyu Chen, Haohang Yang, Rong Ma, Fan Zhu, Xubin Zheng, Xinxing Li, Sen Hou, Zhidong Gao, Jinwen Yin, Francis Ka-ming Chan, Qin Wu, Senyi Deng, Yin Yao, Shengbao Suo, Chuanyu Liu, Longqi Liu , Xun Xu, Yong Hou, Haoran Tao, Yuliang Dong, Tao Zeng, Young Li, Li Zuo, Hua Wang, Xin Liu, Jingying Zhou^#, Zexian Zeng^#, Yu Feng^#. Uncovering ectopic germinal centers for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq.Nat Commun, 3^rdreview.

2.Haorui Zhang*, Zongxu Zhang*, Peiyu Wang*, Tian Xu, Xiaoyu Chen, Yanping Zhao, Siyu Lin, Wenjie Cai, Pengfei Ren, Ce Luo, Peng Zhang, Yunfeng Wang, Sen Hou, Hu Zeng, Zhidong Gao, Yu Feng^#, Deng Pan^#, Zexian Zeng^#.Cell, Accepted.

3.Xiaojuan Zhan, Yi Liu, Yanying Guo, Wenwen Zhou, Yixin Yan, Hui Zeng, Xuan Dong, Xiaoyu Chen, Rong Ma, Zhong Liu, Fan Zhu, Xubin Zheng, Xinxing Li, Jinwen Yin, Francis Ka-ming Chan, Chuanyu Liu, Longqi Liu, Xun Xu, Yong Hou, Haoran Tao, Yuliang Dong, Tao Zeng, Young Li#, Jingying Zhou#, Zexian Zeng#, Yu Feng# (2025). Single cell resolved spatial immune repertoire unveils spatial heterogeneity of lymphoid aggregates in human immune disorders.bioRxiv, 2025-01.https://doi.org/10.1101/2025.01.16.630222

4.Yu Feng*, Wenjuan Ma*, Yupeng Zang, Yanying Guo, Young Li, Yixuan Zhang, Xuan Dong, Yi Liu, Xiaojuan Zhan, Zhizhong Pan, Mei Luo, Miaoqing Wu, Ao Chen, Da Kang, Gong Chen, Longqi Liu, Jingying Zhou, Rongxin Zhang (2024). Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients.Nature Communications, 15(1), 10259.https://doi.org/10.1038/s41467-024-54710-3

5.Rongxin Zhang*, Yu Feng*, Wenjuan Ma*, Yanying Guo, Mei Luo, Young Li, Yupeng Zang, Xuan Dong, Shixun Lu, Qiang Guo, Qumiao Xu, Huanyi Chen, Yijian Li, Longqi Liu, Ao Chen, Gong Chen, Xun Xu(2023). Spatial transcriptome unveils a discontinuous inflammatory pattern in proficient mismatch repair colorectal adenocarcinoma.Fundamental Research, 3(4), 640-646.https://doi.org/10.1016/j.fmre.2022.01.036

6.Weiqin Yang*, Yu Feng*, Jingying Zhou*, Otto Ka-Wing Cheung, Jianquan Cao, Jing Wang, Wenshu Tang, Yalin Tu, Liangliang Xu, Feng Wu, Zhiwu Tan, Hanyong Sun, Yuan Tian, John Wong, Paul Bo-San Lai, Stephen Lam Chan, Anthony Wing-Hung Chan, Patrick Boon-Ooi Tan, Zhiwei Chen, Joseph Jao-Yiu Sung, Kevin Yuk-Lap Yip, Ka-Fai To, and Alfred Sze-Lok Cheng (2021). A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.Science translational medicine, 13(588), eaaz6804.https://doi.org/10.1126/scitranslmed.aaz6804

7.Bingying Luo, Fei Teng, Guo Tang, Weixuan Chen, Chi Qu, Xuanzhu Liu, Xin Liu, Xing Liu, Huaqiang Huang, Yu Feng, Xue Zhang, Min Jian, Mei Li, Feng Xi, Guibo Li, Sha Liao, Ao Chen, Xun Xu, Jiajun Zhang. StereoMM: A Graph Fusion Model for Integrating Spatial Transcriptomic Data and Pathological Images.Briefings in Bioinformatics, 2025-03, https://doi.org/10.1093/bib/bbaf210.

8.Da Kang, Shanshan Huang, Yijun Liao, Siyuan Mi, Jingying Zhou, Yu Feng, Riming Huang, Zhen-hai Lu, Z. Z. Pan, Wenjuan Ma, Gong Chen, Jia-Xing Yue, Jingxiu Huang & R. X. Zhang (2024). Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer.Journal of Translational Medicine, 22(1), 742.https://doi.org/10.1186/s12967-024-05473-4

9.Zhewen Xiong, Stephen Lam Chan, Jingying Zhou, Joaquim SL Vong, Tsz Tung Kwong, Xuezhen Zeng, Haoran Wu, Jianquan Cao, Yalin Tu, Yu Feng, Weiqin Yang, Patrick Pak-Chun Wong, Willis Wai-Yiu Si-Tou, Xiaoyu Liu, Jing Wang, Wenshu Tang, Zhixian Liang, Jiahuan Lu, Ka Man Li, Jie-Ting Low, Michael Wing-Yan Chan, Howard HW Leung, Anthony WH Chan, Ka-Fai To, Kevin Yuk-Lap Yip, Yuk Ming Dennis Lo, Joseph Jao-Yiu Sung, Alfred Sze-Lok Cheng (2023). Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.Gut, 72(9), 1758-1773.https://doi.org/10.1136/gutjnl-2022-328364